Breast and gastric cancer cell lines harboring FGFR2 amplification are highly sensitive to FGFR2 inhibitors in preclinical models [13]–[15], and amplification in both breast and gastric cancer is strongly associated with poorly differentiated, late stage tumors [11], [16]. This evidence concerns the gene FGFR2 and gastric cancer.